Why lutein is on so many labels
Lutein and zeaxanthin are yellow plant pigments (carotenoids) that collect in the macula, the small central part of the retina you use for reading and recognizing faces. Leafy greens like kale and spinach are rich sources, and eye-health supplements often put them front and center.
The reason is two large US government trials in people with age-related macular degeneration (AMD), a leading cause of vision loss in older adults. What those trials found is useful, but it's more specific than most labels suggest.
Take the free supplement quiz →
The original eye-vitamin trial (AREDS)
The AMD part of the Age-Related Eye Disease Study (AREDS) followed 3,640 people aged 55 to 80 for about 6 years. All had at least early signs of AMD, and some already had advanced AMD in one eye. They took high doses of vitamin C (500 mg), vitamin E (400 IU), beta-carotene (15 mg) and zinc (80 mg, with 2 mg copper), or a placebo. Antioxidants plus zinc lowered the odds of developing advanced AMD (odds ratio 0.72) compared with placebo, and the benefit was concentrated in people at higher risk (AREDS Research Group, 2001).
A 2023 Cochrane review, which drew mostly on AREDS, concluded this kind of supplement probably slows progression to late AMD (moderate-certainty evidence). It estimated about 78 fewer cases per 1,000 people with intermediate AMD taking the vitamins, but only about 4 fewer per 1,000 with early AMD, whose risk is low to begin with (Evans & Lawrenson, 2023).
There was a catch: other large trials found beta-carotene may raise lung cancer risk in people who smoke (NEI).
Where lutein and zeaxanthin came in (AREDS2)
The follow-up trial, AREDS2, enrolled 4,203 people aged 50 to 85 with intermediate AMD in both eyes, or intermediate AMD in one eye and advanced AMD in the other. It tested adding 10 mg lutein plus 2 mg zeaxanthin to the formula.
Adding them did not significantly lower progression to advanced AMD overall over a median of 5 years. But more lung cancers occurred in people given beta-carotene (2.0% vs 0.9%), mostly former smokers, so the researchers concluded lutein and zeaxanthin could be an appropriate swap for beta-carotene (AREDS2 Research Group, 2013).
Ten years on, beta-carotene was linked to nearly double the odds of lung cancer (odds ratio 1.82), while lutein and zeaxanthin were not linked to a significant increase. In a secondary analysis, people originally assigned lutein and zeaxanthin were somewhat less likely to progress to late AMD than those assigned beta-carotene, a possible benefit (hazard ratio 0.85; 95% CI 0.73 to 0.98) (Chew et al., 2022).
Based on the 2013 results, the AREDS2 formula swapped beta-carotene for lutein and zeaxanthin, and the 10-year data supported that choice.
| Question | What trials show |
|---|---|
| Slow intermediate AMD? | Probably, as part of AREDS2 formula |
| Prevent AMD? | Not shown (no lutein prevention trials) |
| Prevent cataracts? | No overall effect (AMD trial) |
What it won't do
Prevent AMD in healthy eyes. The National Eye Institute says the AREDS formulas showed no benefit for people with early AMD or no AMD, and that supplements can't prevent AMD (NEI). A Cochrane review of trials in the general population found vitamin E, beta-carotene and vitamin C did not prevent AMD; none of these trials tested lutein or zeaxanthin (Evans & Lawrenson, 2017).
Prevent cataracts. In AREDS2, a trial of people with AMD, lutein and zeaxanthin had no significant overall effect on the need for cataract surgery. A subgroup who ate very little lutein did have fewer cataract surgeries, but that was one secondary finding (Chew et al., 2013).
Who should consider it
As an Amazon Associate we earn from qualifying purchases. This doesn't change what the research says.
If an eye doctor has told you that you have intermediate AMD, or late AMD in one eye, ask them whether an AREDS2 eye vitamin is right for you. Check the label matches the trial doses: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (or 25 mg, see below) and copper 2 mg (NEI).
That zinc dose is twice the general adult upper limit of 40 mg a day (NIH ODS), which is one reason this formula is meant for people with diagnosed AMD, with their doctor's guidance, not as a general "eye health" pill. AREDS2 also tested 25 mg of zinc and found no difference from 80 mg, though only the 80 mg dose has placebo-controlled evidence (NEI), so ask your doctor whether a lower-zinc AREDS2 formula suits you. The copper is there because high-dose zinc can cause copper deficiency. If you smoke now or used to, avoid the original formula with beta-carotene. Tell your doctor or pharmacist what else you take: the vitamin E can interact with some medicines, including blood thinners, cancer drugs and cholesterol-lowering drugs (NEI), and zinc can interact with some antibiotics (NIH ODS).
If your eyes are healthy, there's no trial evidence that a lutein supplement prevents eye disease (Evans & Lawrenson, 2017). Eating leafy greens is a sensible habit, and regular dilated eye exams matter more, especially from middle age on, because early AMD usually has no symptoms (NEI).
See an eye doctor right away if straight lines start to look wavy or crooked, or you notice a blurry or dark spot in the center of your vision. If your vision suddenly gets worse, get urgent care the same day. Wet AMD can be treated, and getting treated early can help stop further vision loss (NEI; NHS).
The bottom line
Lutein and zeaxanthin are best supported as part of the AREDS2 formula, for people with intermediate AMD (or late AMD in one eye), where it probably slows progression to the advanced stage. They haven't been shown to prevent AMD or cataracts. Get a diagnosis first, and choose your supplement with your eye doctor.